This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents high levels of HIV viral load suppression (>90%) in populations receiving dolutegravir (DTG)-containing antiretroviral therapy (ART).

The Department of Pharmaceuticals (DoP) has come out with a draft National Pharmaceuticals Policy (NPP) 2023 emphasising on a holistic policy approach to address the challenges faced by Indian pharmaceutical industries and provide definitive policy interventions to enhance the collective ecosystem.

The Department of Pharmaceuticals (DoP) has notified the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector in India with reforms in terms of regulatory framework and streamlining processes reducing the approval timelines, incentivising investment in innovation and creation of an enabling ecosystem for inn

The Global Action Plan on HIV drug resistance 2017–2021 provided a comprehensive framework for global and country action and outlined a package of interventions and resources to guide the collective response to HIV drug resistance.

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs).

Trafficked medical products kill almost half a million sub-Saharan Africans every year, and action is needed to stem the flow, the United Nations Office on Drugs and Crime (UNODC) states in its new threat assessment report.

The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR.